Trial Profile
Karma CREME-1: A Double-blind, Placebo-controlled, Three-armed, Pilot Study of the Effects, Safety and Tolerability of Topical Endoxifen in Women Within the Karma Cohort
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Endoxifen (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms CREME; Karma CREME-1
- Sponsors Atossa Genetics; Atossa Therapeutics
- 11 Jun 2019 Status changed from active, no longer recruiting to completed.
- 09 Jan 2019 According to an Atossa Genetics media release, this trial is anticipated to complete in the second quarter 2019.
- 11 Oct 2018 Status changed from recruiting to active, no longer recruiting, according to an Atossa Genetics media release.